SCHEMBL25680952

SCHEMBL25680952

Cc1cc(-c2cnn(C3CCCCO3)c2)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.37
MCL1 Q07820 1/20 0.37
FGFR1 P11362 3/20 0.36
FLT3 P36888 2/20 0.36
FGFR2 P21802 1/20 0.36
FGFR4 P22455 1/20 0.36
FGFR3 P22607 1/20 0.36
KDR P35968 1/20 0.36
DDR2 Q16832 1/20 0.35
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35
SYK P43405 1/20 0.34
AURKB Q96GD4 1/20 0.34
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
ABL1 P00519 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18956281 0.87 FGFR1 (0.40) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL24643242 0.84 LIPG (0.42) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL18956280 0.83 FGFR1 (0.39) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL31227254 0.82 MCL1 (0.41) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL25680672 0.82 KDM5B (0.43) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL21425479 0.82 KDM5B (0.37) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL25170651 0.81 MCL1 (0.37) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL21425480 0.81 KDM5B (0.37) KDM5BMCL1FGFR1FLT3FGFR2
SCHEMBL482117 0.81 CYP4F2 (0.33) CYP4F2CYP4A11ABL1
SCHEMBL29101237 0.80 FGFR1 (0.37) KDM5BMCL1FGFR1FLT3FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2023-10-19 US disclosed
US-11780839-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11685746-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, HDAC6 KDM5B 3065/4885MCL1 1745/4885FGFR1 1516/4885
US-11685746-B2 Heteroaryl compounds for treating Huntington's disease HTT, HYPK, HDAC6 KDM5B 3463/4885MCL1 2257/4885FGFR1 1783/4885
US-11780839-B2 Compounds for treating Huntington's disease HTT, HYPK, HDAC6 KDM5B 3065/4885MCL1 1745/4885FGFR1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.